Ultragenyx to Present at Morgan Stanley Healthcare Conference
September 07 2021 - 4:30PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for serious rare and ultra-rare genetic diseases, today
announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief
Executive Officer and President will present at the Morgan Stanley
19th Annual Healthcare Conference on September 14, 2021 at 4:15 PM
ET.
The live and archived webcast of the presentation
will be accessible from the company’s website at
http://ir.ultragenyx.com/events.cfm. The replay of the webcast will
be available for 90 days.
About Ultragenyx Pharmaceutical
Inc.Ultragenyx is a biopharmaceutical company committed to
bringing novel products to patients for the treatment of serious
rare and ultra-rare genetic diseases. The company has built a
diverse portfolio of approved therapies and product candidates
aimed at addressing diseases with high unmet medical need and clear
biology for treatment, for which there are typically no approved
therapies treating the underlying disease.
The company is led by a management team experienced
in the development and commercialization of rare disease
therapeutics. Ultragenyx’s strategy is predicated upon time- and
cost-efficient drug development, with the goal of delivering safe
and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit
the company's website at: www.ultragenyx.com.
ContactsUltragenyx Pharmaceutical,
Inc.InvestorsJoshua Higa415-660-0951
MediaCarolyn Wang415-225-5050
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Historical Stock Chart
From Apr 2023 to Apr 2024